Tradelearner2022

$IOVA -Drastically Reduced Addressable Market and Delayed Label Expansion Because lifileucel proved largely ineffective in KRAS-mutant lung cancer, the commercial premise of a broad second-line NSCLC market was severely reduced: Iovance announced it is capping enrollment in the current general IOV-LUN-202 cohort at approximately 80 patients. The company must now launch a new, biomarker-enriched cohort called POSITILITY in November 2026 to enroll only this targeted subgroup with registrational intent. This shifts the regulatory submission in 2027 from a broad, general NSCLC approval to a much smaller, biomarker-defined niche of lung cancer patients.

$IOVA -$IOVA — What’s Behind the After-Hours Move - New catalyst: At 7:00 p.m. ET on October 28, Iovance announced a webcast to discuss positive results from its IOV-LUN-202 Phase 2 registrational cohorts in previously treated nonsquamous metastatic non-small cell lung cancer. The announcement did not disclose numerical efficacy results. The webcast is scheduled for October 29 at 8:30 a.m. ET. Announcement - Price reaction: After a $14.81 regular-session close, observed after-hours trading reached $17.62 by 7:21 p.m. ET, approximately +19.0%. This is a timestamped observation not the final after-hours high or closing price. - Earlier sarcoma data: On October 26, Iovance reported four confirmed partial responses among eight evaluable patients—50% ORR—in a pilot study of lifileucel in two advanced soft-tissue sarcoma subtypes. All four responses remained ongoing at the September 9 data cutoff. The small sample warrants caution. Company release - Earlier melanoma data: On October 23, a separate 24-patient Phase 2 study of lifileucel plus pembrolizumab reported 62.5% ORR, 29.2% complete responses, and median overall survival not reached at 50.9 months of median study follow-up. These figures should not be confused with the upcoming lung-cancer results. Company release - Short-interest context: Reported short interest was 58.93 million shares as of October 15, with 4.43 days to cover. That indicates meaningful short positioning, but it does not establish that tonight’s rally was a forced short squeeze. Short-interest data - What matters next: The webcast’s patient count, confirmed response rate, response durability, safety findings and regulatory pathway. Positive clinical language is encouraging; the detailed results will determine how much it changes the investment case. The announcement is real. Further upside, a confirmed support level and a short squeeze remain unproven. Good luck to everyon

$AIOK — Next Week’s Price Scenarios, Catalysts & Valuation Math Upside scenario: A recovery toward $11.13–$12.02, with $15.59 becoming a possible retest only if buyers rebuild momentum and clear resistance. These are conditional scenarios—not guaranteed targets. The preliminary $16.19 asset reference is not a verified intrinsic value or next-week price forecast. 📊 What price action tells us Last checked Friday after-hours price: approximately $9.18 at 6:59 p.m. Eastern. Friday’s regular-session close: approximately $12.02. Friday’s high: $15.59. From the $9.18 reference:$11.13 = approximately 21% upside. $12.02 = approximately 31% upside. $15.59 = approximately 70% upside. Those percentages describe distance to reference levels—not the probability of reaching them. The after-hours reversal shows that buyers have not yet sustained Friday’s higher prices. A constructive recovery would require stabilization, a higher low, recovery above the new session’s VWAP, and sustained buying through resistance. A break below the observed $9.10 after-hours low would weaken that recovery scenario. It is not guaranteed support. 💵 Catalyst #1: $3.50 special dividend AIOK declared a $3.50 special dividend per common share. Announced record date: November 2. Expected payment date: November 25. Cash is the default, with a stock-election alternative using a $4.5159 reference price, subject to the company’s right to require cash settlement. At $9.18, the distribution equals approximately 38.1% of the stock price. That is not a guaranteed 38.1% return: distributing cash reduces the company’s remaining assets, and the stock can adjust accordingly. Dividend entitlement depends on the applicable trading and due-bill arrangements; the record date alone does not explain who receives the payment. Stock elections would change the share count and require recalculating per-share values. Dividend filing 🚢 Catalyst #2: Proposed $18 million vessel sale AIOK agreed to sell the Dream Arrax LPG carrier for $18 million. Closing is expected in Q4, subject to customary conditions. The company would retain one LPG carrier afterward. Completing the sale would convert a vessel into cash and increase liquidity. The buyer is a Robin Energy subsidiary; Robin Energy is controlled by AIOK’s chairman and CEO. Independent board committees reviewed the transaction, but the related-party relationship remains relevant. The sale proceeds are not automatically $18 million of new profit: the vessel already has a carrying value on the balance sheet. Transaction details 🧮 Where the $16.19 asset reference comes from Historical June 30 net assets after liabilities: $49,922,956. Add spin-off cash contribution: $45,000,000. Pro forma net assets: $94,922,956. Subtract preferred liquidation claim: $25,000,000. Preliminary amount attributable to common shares: $69,922,956. Divide by 4,319,916 common shares. Result: approximately $16.19 per common share. This is a historical, pro forma asset calculation—not a current liquidation appraisal. Vessel values, related-party receivables, subsequent operating changes, costs and potential dilution still require reconciliation. Company disclosures, Preferred-share terms ⚠️ Avoid double-counting the dividend Assuming an entirely cash dividend and unchanged share count: $3.50 × 4,319,916 shares = $15,119,706 distributed. Remaining preliminary asset reference: ($69,922,956 − $15,119,706) ÷ 4,319,916 = approximately $12.69 per share. The framework is therefore approximately $3.50 distributed + $12.69 remaining, before subsequent changes. Adding $3.50 to $16.19 would double-count the distribution. Adding the full $18 million vessel-sale proceeds without removing the vessel’s carrying value would also overstate assets. 🔎 What the short-selling evidence actually shows Friday’s IBKR-sourced borrow availability fell:50,000 shares → 8,000 shares → zero. That indicates tighter availability at that broker. The displayed annualized borrow fee was 3.64%, down from 4.54% earlier. We therefore have evidence of reduced availability, but no demonstrated surge in borrowing costs. Zero availability at one broker does not prove marketwide scarcity, active covering or an imminent squeeze.Borrow data FINRA reported approximately 12.975 million short-sale shares out of 22.560 million shares of covered off-exchange volume: 57.51%. This measures transaction activity—not outstanding short positions. It does not mean 57.51% of the float is short. Reliable outstanding short interest and days-to-cover remain unverified. FINRA data, Explanation 📌 Does the dividend force shorts to cover Monday? No verified Monday covering deadline has been established. Borrowers generally owe equivalent dividend payments when their positions carry the applicable entitlement. However, the stock’s ex-distribution price adjustment can economically offset that payment. Recalls or margin pressure could force covering, but neither has been established here. A squeeze is possible; confirmed covering is a different claim. SEC explanation 🏛️ Ownership and potential supply matter PaniCorp holds approximately 74.2% of disclosed common shares, creating concentrated ownership. Concentration can amplify price moves in either direction. The company has filed a $500 million primary shelf and registration for resale of 3.206 million shares. These represent potential future supply—not proof that issuance or selling has occurred. Registration filing 🎯 My outlook Conditionally bullish, based on the announced distribution, proposed asset monetization and preliminary asset-value gap. $11–$12 is a recovery scenario requiring renewed demand. $15.59 is a more demanding continuation scenario. $16.19 is an asset reference—not a promised trading price. Friday’s after-hours weakness needs to be respected. The investment case should rest on assets, execution and price confirmation—not a claim that shorts must buy next week. 4:26 PM

$TNGX- The pullback in $TNGX reflects a textbook biotech "sell the news" reaction rather than a clinical breakdown. After running aggressively into the ESMO data release, shares are de-risking as short-term momentum traders exit and the market digests a Phase 3 initiation timeline set for early 2027. Clinically, however, the updated Phase 1/2 readout for vopimetostat (TNG462) in combination with RAS(ON) inhibitors demonstrated unprecedented biological activity in pancreatic cancer, transforming a high-risk early-stage asset into a de-risked, registrational-stage program. The Bull Case in 5 Core Points: Unprecedented Response in Pancreatic Cancer: In heavily pretreated (3L) MTAP-deleted PDAC—where historical chemotherapy response rates hover under 15%—the combination with daraxonrasib delivered an 82% ORR and an 88% 9-month progression-free survival (PFS) rate, with zero progressive disease at data cutoff. Flawless Safety at Registrational Dose: Zero dose-limiting toxicities (DLTs) and 0% treatment-related discontinuations were observed at the recommended Phase 3 dose; treatment-related adverse events were predominantly low-grade (stomatitis, rash), with a manageable 15%–20% dose-reduction rate. Direct Leap to Frontline (1L): Tango is bypassing incremental niche trials to advance directly into a randomized, global Phase 3 trial against standard-of-care chemotherapy in first-line pancreatic cancer, capturing a substantially larger multi-billion-dollar addressable market. $1B Balance Sheet Shield: With roughly $1.0 billion in cash and marketable securities, the company is fully funded through pivotal Phase 3 milestones, eliminating the near-term dilution and discounted secondary offering overhang typical of clinical biotechs. Asymmetric Risk/Reward on the Tape: Wall Street consensus price targets remain anchored around $43–$45 (implying 80%+ upside). With elevated short interest and an overblown initial tape flush, any exhaustion in selling volume provides the setup for a rapid technical mean reversion.

$INO -The Realistic Bull Case for $INO to $1.50: Why the Market is Mispricing the $80M Win Ahead of October 30 The headline $80.4 million court award spiked $INO by over 20% before profit-taking brought it back to earth. While retail calls for $3.00+ ignore share count and warrant math, $1.50 is a realistic, mathematically grounded near-term target. Here is the breakdown of why $1.50 makes fundamental sense and how the next 10 days could trigger the move: 1. The Math: What Does $1.50 Actually Mean? Current Share Count: ~103.4 million shares Market Cap at $1.00: ~$103.4 million Market Cap at $1.50: ~$155.1 million Added Value Needed: +$51.7 million At $1.50, the market only needs to price in a probability-weighted recovery of the litigation ($20M–$30M in real value) combined with lead pipeline validation. That is completely within reach.

$INO -Appellate Mechanics and the Supersedeas DilemmaUnder Pennsylvania civil procedure, obtaining a final trial court judgment does not trigger immediate cash disbursement if the defendants pursue post-trial motions or appeals. However, Pennsylvania law places stringent security requirements on judgment debtors seeking to stay execution pending appeal.The 120% Supersedeas Bond RequirementPursuant to Pennsylvania Rule of Appellate Procedure 1731(a) (Pa. R.A.P. 1731(a)), an appeal from an order involving solely a monetary award does not operate as an automatic supersedeas (stay of execution) unless the appellant posts security in the amount of 120% of the judgment amount found due and unpaid, plus interest and anticipated delay costs.$$\text{Required Supersedeas Security} = \$80,416,101 \times 120\% = \$96,499,321.20$$COMMERCIAL sureties require corporate appellants to deposit 100% liquid collateral—typically cash, irrevocable letters of credit, or investment-grade securities—before underwriting an appeal bond of this size, alongside an annual premium running approximately 1% of the bonded total. Because GeneOne’s market capitalization is approximately $35 million and its cash balances are limited, neither GeneOne nor VGXI has the liquidity required to collateralize a $96.5 million surety bond.

$VCIG - separating the AI catalyst from the financing and float confusion VCI Global announced on October 6 at 3:45 p.m. ET that its VGAIN Compute platform is live, allowing users to purchase AI usage tokens to access supported models, including GPT, Kimi, Llama and Qwen. This is a company-confirmed product launch. Supporting those models does not establish partnerships with their developers, and “AI tokens” here does not establish a cryptocurrency launch. The release does not disclose paying customers, revenue or margins. Announcement The $125M financing headline is not $125M cash received. It describes conditional equity-purchase capacity. The associated Form D reports $0 sold under that offering. The financing includes discounted share-purchase mechanics and warrants, creating potential dilution. Conversely, proposed registration of up to 111.6M shares does not mean all those shares are already outstanding or available to sell today. Form D, F-1 Treat float claims cautiously. The September 29 filing reports 2.077M outstanding shares. Adding the subsequent 193,349-share CEO subscription produces approximately 2.271M basic shares, assuming no other changes. A reconstruction after identified insider/restricted holdings suggests roughly 1.9M, but that is not a confirmed current float. Sub-500K claims should not be treated as established. CEO filing Book value is not a price target. At December 2025, the company reported $116.9M in assets, including a $62.8M related-party receivable, versus approximately $941K cash and $20.7M liabilities. Those historical balances require updated collection and financing information before translating them into per-share value. Annual report VCIG has a genuine product announcement and speculative upside potential. It does not yet have disclosed platform economics supporting a reliable intrinsic-value target. Neither “guaranteed squeeze” nor “all the financing shares are dumping now” is established by the evidence. Watch for customer adoption, cash collections, actual issuance and sustained buying not just headline size.

$SNDK - One of the fascinating charts ever. It took almost a year to find its ATH (which itself was a record and wealth creator) now the rate it is coming down is unparalleled. No support at all. Let's see what happens in the next few days. We can only speculate. None of us know

$HPE - Friday movement. It is not just because of DELL sympathy.. the fundamental backdrop kept the bids firm ahead of the mi day earnings : Activists & Insiders: Elliott Management's newly expanded 27.4M share stake continues to fuel structural optimization hopes. Balance Sheet De-leveraging: $HPE disclosed the monetization of its H3C stake for roughly $987M, giving them clean capital to pay down debt post-Juniper.

$HPE -Can it hit $50 after hours on Monday ? If HPE drops a true beat after the close (EPS well above the $0.55 whisper, an expansion of the $5B AI backlog, and a major upward revision to full-year FY26 guidance), the 10.6% post-market implied volatility will unlock. A 12% to 15% gap up from a $44 baseline in late-theater trading is exactly where a squeeze to $50 would happen

$CRCL -Speculation only.. bullish, specifically anticipating a high probability of a short squeeze that pushes the stock into the $130.00 to $134.00 range, or potentially higher. Here is the data-driven rationale for this bullish lean: 1-The CLARITY Act is a Massive De-Risking Event: The recent bipartisan compromise on the CLARITY Act explicitly protects the transaction-based rewards that Circle relies on for its business model. This fundamentally removes the existential regulatory overhang that was depressing the stock, paving the way for institutional adoption. 2-The "Powder Keg" Short Setup: Short sellers have aggressively targeted the stock due to fears of margin contraction, with short interest jumping 22.4% recently to cover 12.2% of the float. Even more telling, the daily short volume ratio surged to a staggering 48.11% of all trading volume just days before the earnings blackout. If Circle reports even mildly positive forward guidance regarding their high-margin software services, these short sellers will be forced to rapidly buy back shares to cover their positions, creating a violent upward price spike. 3-Historical Precedent: Circle has a history of massive post-earnings rallies. Following their last earnings report in February, the stock surged 35.5% in a single day after beating EPS estimates. While the high valuation and recent insider selling (which was largely pre-scheduled via 10b5-1 plans) provide ammunition for the bears, the structural setup in the options market and the heavily squeezed float suggest the path of least resistance is a violent move upward. If management executes a strong earnings call, expect the stock to hit the top of the options market's 15% expected move (around $130) and potentially challenge Wells Fargo's recent $142.00 price target.

$SHAZ- The $SHAZ "Sovereign AI" Inflection: A $1.25B Masterclass 1/ The Catalyst: SharonAI ($SHAZ) just dropped a nuclear-grade 8-K. A 5-year, $1.25 Billion Master Infrastructure Agreement with ESDS Software Solutions. The Scale: For a ~$445M market cap company, this is a TCV-to-Cap ratio of 2.8x. The Math: Amortized over 60 months, that’s ~$250M/year in high-margin recurring revenue. 2/ The Hardware Moat: This isn't a "pilot" program. It’s a deployment of 8,200 NVIDIA B300 (Blackwell Ultra) GPUs. The Performance: 14 PFLOPS dense FP4 compute 55% faster than the B200. The Infrastructure: 1,400W TDP per GPU requires Direct Liquid Cooling (DLC). The Edge: $SHAZ has 70MW of Tier IV capacity secured at @NEXTDC M3 in Melbourne. In a power-constrained world, Capacity = Alpha. 3/ Counterparty De-Risking: The bear case today was skepticism over ESDS’s ability to pay. The 8-K silenced this with cold data: Security: ESDS is mandated to provide $140M in Letters of Credit/Bank Guarantees. Lock-in: No "Termination for Convenience" in the first 36 months. This isn't "hope"; it's a collateralized asset. 4/ Financial Engineering: $SHAZ is scaling without the "Death Spiral" dilution common in tech micro-caps. USD.AI Facility: A $500M non-recourse, asset-backed debt engine. The Tech: Financing via stablecoin liquidity against verified GPU hardware. The Result: Massive scaling of the "AI Factory" while keeping the float tight (~10.8M share float). 5/ The Tape (The "Gap & Crap" Recovery): Today was a textbook technical shakeout. The Open: Gapped to $25.80. The Trap: Flushed to an intraday low of $22.54 to shake out "paper hands." The Absorption: Heavy institutional accumulation drove a recovery to close at $27.62 (+21.5%). 6/ Valuation Framework: If $SHAZ executes on a $275M-$300M revenue run-rate: Peer Multiples: Neocloud peers (CoreWeave/Lambda) trade at 8x-12x Revenue. Conservative 6x Multiple: Implies a $1.8B Market Cap. Target: With current share structure, "Fair Value" sits north of $75.00 as the market prices in the backlog. 7/ The Verdict: We are witnessing an Episodic Pivot (A+ Catalyst). Today was Day 1 of the structural re-rating. Once the market reclaims the $30.00 IPO price, we enter "Blue Sky" territory.

$RZLV- Not bad for 22% spike today.. . sometimes analysis do work. sometimes it does not..

$RZLV -$RZLV 20-F ALERT: The "Audit" is In – Hypergrowth Validated-sec.gov/Archives/edgar/data/… wait is over. Rezolve AI has officially filed its Form 20-F Annual Report with the SEC. If you were looking for the "Green Light" that separates speculative AI rumors from production-grade reality, this is it. -The "Triple Crown" Metrics The 543% Growth Flip: 2025 revenue hit $46.8M, but the real story is the H2 acceleration. Revenue skyrocketed 543% in the second half vs. the first half as major deployments went live. The "Floor" is Set: The company exited the year with $19.4M in December MRR, establishing a $232M+ Annualized Run Rate (ARR). This provides a massive, high-conviction foundation for their raised $360M revenue guidance for 2026. Software-Elite Margins: Blended gross margins are at 66%, but the core software component is performing at 90%+. This is the structural profitability "Whales" look for in the SaaS/AI sector. -The "Fully Funded" Mandate The biggest "short" thesis on small-cap AI is always dilution. The 20-F just killed that narrative. Cash Position: $111.1M as of year-end. Capital Fortress: With over $750M in total funding secured (including the oversubscribed Jan raise), the Company explicitly stated they have "zero requirement for additional operational equity" to execute their 2026 mission. -Strategic Edge: Agentic Commerce This isn't just "Search." Rezolve has processed 112.7 billion API calls across 950+ enterprise customers. They are moving from the "Experimentation Phase" into Live Infrastructure. 📉 The Technical Setup (Tuesday Morning) The Gap: The stock is already showing relative strength, drifting green overnight as the "Compliance Risk" of the missing 20-F is removed. T Bottom Line: The 20-F proves the "Hockey Stick" is real. $RZLV is no longer a concept it’s an infrastructure leader trading at a massive discount to its Forward ARR. #RZLV #AI #AgenticCommerce #Squeeze #StockMarket

$RZLV -The $RZLV numbers this morning are essentially a masterclass in AI scaling. While the "Tape" is playing tug-of-war at the $2.60 level, the fundamental re-rating is hard to ignore: 🔹 The Growth: 543% H2 revenue surge vs. H1. 🔹 The Guide: 2026 revenue raised to $360M (well above previous $310M estimates). 🔹 The Floor: Exited 2025 with $232M in contracted ARR. That's a massive safety net for a ~$1B market cap. 🔹 The Cash: $750M+ total funding. The "dilution" bear case is officially dead. Why the stagnation? Look at the data: Shorts borrowed 2.5M+ shares today alone to hold this back, and there's a massive Call Wall at $3.00. The Setup: Historically, $RZLV is a "Day 2" mover (Avg +15% continuation). If this clears the $2.89 HOD, the shorts are trapped with near-zero availability to borrow more. Watching the 20-F filing today as the final "green light" for the Whales. 🐳 #AI #Stocks #Trading #RZLV $RZLV

$IBRX 48-Hour Forensic Update: The "Quiet" Battle for the Floor. It has been two days since the FDA Warning Letter triggered a -21% shock. While the narrative has been dominated by "Management Risk," the actual data from the last 48 hours tells a story of aggressive institutional defense and clinical validation. 1. The Clinical Counter-Punch (March 26) While management is effectively "benched" from making promotional claims, they just dropped a massive clinical update this morning. QUILT-2.005 Milestone: The Independent Data Monitoring Committee (IDMC) confirmed the pivotal trial for BCG-Naïve patients (first-line) is adequately powered to show statistical significance. Why this matters: This isn't the "failed" monotherapy cohort. This is the primary expansion market. A supplemental BLA (sBLA) for this multi-billion dollar indication is now officially on track for Q4 2026. This effectively separates the "marketing noise" from the "clinical signal." 2. Technical Resilience: The $7.20 Floor The "Flush" Reversal: On March 24, the stock hit a terrifying low of $6.54. The Recovery: Since that low, the stock has battled back to hold the $7.30–$8.00 range. Today (March 26), it even tested $8.43 before the shorts attempted to cap it. Volume Analysis: After the 86M share "liquidation" on Tuesday, volume has normalized, suggesting that the "Panic Sellers" have been flushed out and replaced by "Whale" accumulation. 3. Market Microstructure: The Short Squeeze Setup The "Silence Trap" we anticipated is backfiring on the shorts: Utilization remains at 100%: There is zero "legal" inventory left to borrow. Cost to Borrow (CTB): Has surged to 17% today. Shorts are paying a heavy premium to bet against a company that just confirmed its trial is powered for success. Put-Call Ratio: The 1.32 ratio for the March 27 weekly expiration shows high bearish positioning the exact fuel needed for a "gamma squeeze" if the stock reclaims $8.50. 4. Regulatory Reality Check SEC EDGAR Audit: Still no 8-K responding to the FDA or new equity offerings. Management is following the 15-day compliance window to the letter. The May 8 "Ace": The market is waiting for the sBLA Acceptance for the Papillary indication. If that drops during this high-CTB/Low-inventory environment, the recovery to $10.00+ could be instantaneous. Final Verdict The "Management Silence" is a legal requirement, not a sign of failure. The clinical data (QUILT-2.005) is the true north. We are currently watching the shorts pay 17% interest to defend a "marketing" headline while the clinical value continues to compound. Capital preservation was the play on Tuesday. Strategic observation is the play today. #IBRX #ANKTIVA #BiotechIntel #StockMarket

$DNLI-AVLAYAH is widely considered the most significant biotech catalyst of 2026: 1. It Solves the "Holy Grail" of Biology For 30 years, the biggest "graveyard" in medicine has been the Blood-Brain Barrier (BBB). Thousands of drugs have failed because they simply couldn't get into the brain. • The Significance: AVLAYAH is the first-ever medicine to use a "Transport Vehicle" (TV) to trick the brain into letting it pass. • The Impact: By approving this, the FDA didn't just approve one drug; they validated a delivery platform that can now be used for Alzheimer’s, Parkinson’s, and ALS. This is the "Intel Inside" moment for brain medicine. 2. The "Competitive Vacuum" In February 2026, the FDA rejected REGENXBIO’s gene therapy for Hunter syndrome. • The Reality: That rejection left the entire market wide open. Denali now has a monopoly on treating the neurological symptoms of this disease. In the world of rare diseases (Orphan Drugs), a monopoly usually leads to massive, high-margin revenue and a multi-billion dollar valuation "re-rating." 3. The "Royalty Pharma" Stamp of Approval Royalty Pharma (the "Whale of Whales" in biotech funding) didn't just bet on Denali they put $275 million on the line specifically for this approval. • The Significance: These guys are the smartest math-minds in the sector. They don't gamble. Their $275M investment was a "pre-approval" bet that the TV platform was worth billions.

$DNLI- WHY WAS IT REMOVED? (THE "GHOST" LISTING) 1.Administrative "Fat Finger" or Early Sync: The FDA’s digital databases (Drugs@FDA, Orange Book, etc.) often sync data from internal review servers to public servers in "batches." It is highly common for a drug to be populated onto the public site hours or even days before the official announcement, and then pulled down once the agency realizes the public has spotted it before the formal 8-K filing or press release. 2.Staging for the News: This is a strong signal that the Approval Letter has likely been signed, and the FDA web team was simply "staging" the page. The removal is a "clean-up" to ensure the official announcement follows the proper regulatory protocol. 3.Historical Precedent: We saw this exact behavior with several high-profile approvals (e.g., Biogen’s Leqembi). The "leak" through the database leads to a pre-market spike, the removal causes a temporary "dip" of uncertainty, and the official press release finally triggers the real squeeze.

$DNLI- $DNLI: Technical & Regulatory Synthesis — April 5 PDUFA As Denali Therapeutics approaches the FDA decision for tividenofusp alfa (DNL310), the equity exhibits a rare convergence of institutional accumulation and mechanical supply constraints. 1. Institutional Activity at Current Levels Level 2 tape captured a ~237k share print (~$5M+) at $20.97 during the March 24 session suggesting meaningful institutional participation at this price zone ahead of the catalyst window. 2. Clinical De-risking Phase 1/2 data demonstrated a 91% reduction in CSF heparan sulfate the key CNS biomarker of disease published in the NEJM. CMC review is complete, materially reducing the probability of a technical rejection. 3. Mechanical Gamma Trap The April 17 option chain shows concentrated Open Interest at the $22.50 strike (832 contracts). A sustained move through $22.50 triggers a Gamma Flip forcing market makers into a pro-cyclical delta-hedging cycle that mechanically accelerates price discovery higher. 4. Liquidity Bottleneck 9.63 Days to Cover. NYSE closed Good Friday April 3. Short sellers have a compressed 7-trading-day window to de-risk ahead of the binary. This creates a structural time-decay trap for the bearish thesis. 5. Platform Optionality 3,050 June $30 calls represent the largest single OI block in the entire chain. The market isn't just pricing tividenofusp alfa — it's beginning to re-rate Denali's broader Blood-Brain Barrier Transport Vehicle platform across Sanfilippo, Pompe, and Alzheimer's programs. 6. The Terminal Exit Risk/reward remains optimal for a Pre-PDUFA Drift strategy. The terminal liquidity point is Thursday April 2. The path of least resistance points toward the 52-week high of $23.77 and the secondary liquidity zone of $25.00. Not financial advice. Do your own work. $966M cash. Breakthrough Therapy designation. No AdCom. Cleared competition. Clock is ticking. ⏱️ #DNLI #Biotech #MarketMechanics #InstitutionalFlow

$IBRX- Tough end of day report - March 24th 2026. Part of investing. $IBRX Forensic Recap: March 24, 2026 Today was a masterclass in how regulatory news collides with extreme market microstructure. The long-term Anktiva thesis hasn't changed but today's -21% crash was driven by a specific information shock. --- 1/ THE CATALYST: FDA Warning Letter FDA Warning Letter MARCS-CMS 725468 was issued March 13 but not publicly disclosed until the FDA posted it on their website today, March 24. During that window, the company announced major wins the NCCN Guideline update (Mar 17) and Macau Approval (Mar 20). IMPORTANT: Companies are not always required to file an 8-K for warning letters materiality is a judgment call. We are not alleging deliberate concealment. What we are saying is the timing created an information asymmetry that the market repriced violently today. --- 2/ THE "SLAP" The FDA cited "false or misleading" claims in: • A direct-to-consumer TV ad featuring CEO Adcock & Dr. Soon-Shiong • A Jan 19 podcast on The Sean Spicer Show Key violations: • Implied Anktiva could "treat all cancers" • Described it as a "cancer vaccine" not an approved label • Showed arm injections (it's delivered intravesically into the bladder) • Zero risk disclosures in the podcast This is their THIRD FDA enforcement action in 6 months. That pattern matters. --- 3/ STATUS This is a marketing/compliance issue NOT a clinical one.Anktiva's 700% revenue growth is real. The FDA is not questioning the science or the approval. They're questioning how management is talking about it publicly. The company has 15 *working* days to respond (~April 15). Expect relative quiet from management during this period as they coordinate their response. --- 4/ PRICE ACTION • Open: $9.07 • Intraday low: $6.54 (-30% peak-to-trough) • Close: ~$7.42 (showed real resilience off lows) • Volume: ~86.9M shares roughly 4x avg daily volume That closing bounce matters. It suggests some buyers stepped in at the lows. But the structure is damaged short-term. --- 5/ SHORT INTEREST & THE SILENCE TRAP Short interest remains ~35.41% of float (~132M+ shares short). Borrow utilization is pinned near 100%. With management now in a regulatory response period (~15 working days), expect a relative news vacuum. Shorts will likely use this silence to test the $6.00–$6.50 support zone. Note: High "Short Exempt" volume seen today reflects legal market-maker exemptions to the uptick rule NOT naked short selling. Important distinction. --- 6/ THE BOTTOM LINE The science hasn't changed. The revenue trajectory hasn't changed. But management credibility has taken a hit both from the content of the letter AND the timing of its disclosure. We are now in a high-volatility "wait and see" period. Two catalysts that can reset the narrative: 📍 ~April 20 — Saudi Arabia commercial launch 📍 ~May 8 — FDA sBLA filing decision (papillary bladder cancer) Not financial advice. Do your own due diligence. Patience and capital preservation are the only plays here. #IBRX #ANKTIVA #TradingIntel #Biotech